Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PHASE-I TRIAL OF RECOMBINANT INTERLEUKIN-3 BEFORE AND AFTER CARBOPLATIN ETOPOSIDE CHEMOTHERAPY IN PATIENTS WITH SOLID TUMORS - A SOUTHWEST-ONCOLOGY-GROUP STUDY
Autore:
RINEHART J; MARGOLIN KA; TRIOZZI P; HERSH E; CAMPION M; RESTA D; LEVITT D;
Indirizzi:
SW ONCOL GRP,OPERAT OFF,SWOG-9026,14980 OMICRON DR SAN ANTONIO TX 78245 TEXAS A&M UNIV,SCOTT & WHITE MEM HOSP & CLIN,COLL MED,HLTH SCI CTR TEMPLE TX 76508 CITY HOPE NATL MED CTR DUARTE CA 91010 OHIO STATE UNIV,COLL MED COLUMBUS OH 43210 UNIV ARIZONA,ARIZONA CANC CTR TUCSON AZ 00000 SANDOZ PHARMACEUT CORP E HANOVER NJ 00000
Titolo Testata:
Clinical cancer research
fascicolo: 10, volume: 1, anno: 1995,
pagine: 1139 - 1144
SICI:
1078-0432(1995)1:10<1139:PTORIB>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLONY-STIMULATING FACTOR; BONE-MARROW FAILURE; GM-CSF; HEMATOPOIESIS; MACROPHAGE; PRIMATES; SYNERGISM; CELLS; IL-3; DIFFERENTIATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
20
Recensione:
Indirizzi per estratti:
Citazione:
J. Rinehart et al., "PHASE-I TRIAL OF RECOMBINANT INTERLEUKIN-3 BEFORE AND AFTER CARBOPLATIN ETOPOSIDE CHEMOTHERAPY IN PATIENTS WITH SOLID TUMORS - A SOUTHWEST-ONCOLOGY-GROUP STUDY", Clinical cancer research, 1(10), 1995, pp. 1139-1144

Abstract

Recombinant human interleukin 3 (rhIL-3, expressed in Escherichia coli) is a hematopoietic growth factor with protean biological effects onbone marrow in animal models, including enhanced granulocyte and platelet production and the capacity to ameliorate chemotherapy-induced bone marrow toxicity. We, therefore, undertook a Phase I trial in patients with advanced solid tumors and normal bone marrow function. Cohortsof four to six patients each received daily s.c. doses of rhIL-3 (SDZ-ILE-964; Sandoz) at dose levels of 1.0, 2.5, 5.0, and 10.0 mu g/kg according to the following schedule: cycle 1, rhIL-3 days 1-14; cycle 2,carboplatin (350 mg/m(2)) on day 1 and etoposide (100 mg/m(2)) on days 1-3; and cycle 3, carboplatin (350 mg/m(2)) on day 1, etoposide (100mg/m(2)) on days 1-3, and rhIL-3 on days 4-17. Each cycle was a totalof 28 days. An analysis of 20 patients entered into all four escalating dose levels revealed that, during cycle 1, absolute neutrophil count (ANC) increased from a median baseline of 6,643/mm(3) to a median of12,692/mm(3), and platelets increased from a median baseline of 314,000/mm(3) to a median of 465,000/mm(3). When cycle 2 was compared with cycle 3, the median ANC nadir increased from 192/mm(3) to 988/mm(3), and the mean ANC nadir increased from 458/mm(3) to 1,297/mm(3). Median platelet count nadirs increased from 29,000/mm(3) to 84,000/mm(3), andthe mean nadir platelet counts increased from 72,000/mm(3) to 129,000/mm(3). Total days on which platelets were <50,000/ mm(3) was 52 for cycle 2 and 19 for cycle 3. The maximum tolerated dose of rhIL-3 was 5.0 mu g/kg/day; dose-limiting toxicities included fatigue, chills, fever, and headache. These data suggest a clear but variable biological activity observed with IL-3, as measured by the reduction in the depth and duration of thrombocytopenia and/or neutropenia when cycle 2 was compared with cycle 3. rhIL-3 is a promising cytokine that may help to ameliorate the bone marrow toxicity observed with the use of chemotherapeutic agents.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/09/20 alle ore 09:34:38